A new biopharmaceutical company has formed after acquiring late-stage clinical drug assets from a slumping public company.
The developer paid $4.15 million for eight parcels totaling just under two acres. The project is tied to community benefits ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果